Advance Search
ZHENG Leizhen, LIU Xianli. Comparison in efficacy of neoadjuvant chemotherapies combined with surgery for advanced gastric cancer[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 26-29. DOI: 10.7619/jcmp.20201637
Citation: ZHENG Leizhen, LIU Xianli. Comparison in efficacy of neoadjuvant chemotherapies combined with surgery for advanced gastric cancer[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 26-29. DOI: 10.7619/jcmp.20201637
shu

Comparison in efficacy of neoadjuvant chemotherapies combined with surgery for advanced gastric cancer

  • Department of Gastroenterology, First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, 471000

More Information
  • Received Date: December 08, 2020
  • Available Online: March 22, 2021
  • Published Date: March 14, 2021
    Graphical Abstract
    • Abstract
  •   Objective  To evaluate the efficacy and safety of neoadjuvant chemotherapies combined with surgery in the treatment of advanced gastric cancer.
      Methods  A total of 74 patients with advanced gastric cancer were randomly divided into two groups, with 37 cases in each group. The control group received preoperative chemotherapy by capecitabine and oxaliplatin (XELOX), while the observation group received S-1 and oxaliplatin (SOX) as neoadjuvant chemotherapy. One week after chemotherapy, patients received surgical treatment according to their conditions. The efficacy and safety of different methods were compared.
      Results  After treatment, the total remission rate of the observation group was significantly higher, and tumor markers such as carbohydrate antigen 724 (CA724), carbohydrate antigen 242 (CA242), carbohydrate antigen 199 (CA199) and carcinoembryonic antigen (CEA) levels were significantly lower than those in the control group(P < 0.05). The 12-month survival rate was significantly higher, and the incidence rates of adverse reactions of hand-foot skin reaction and liver function injury were significantly lower than those of the control group(P < 0.05).
      Conclusion  SOX neoadjuvant chemotherapy combined with surgery for advanced gastric cancer can improve the survival rate of patients, and has lower incidence rate of adverse reactions than XELOX therapy.
    • FullText(HTML)
    • References (15)
  • [1]
    左婷婷, 郑荣寿, 曾红梅, 等. 中国胃癌流行病学现状[J]. 中国肿瘤临床, 2017, 44(1): 52-58. doi: 10.3969/j.issn.1000-8179.2017.01.881
    [2]
    陈丽苹, 贾鑑慧, 于清蕊. 进展期胃癌辅助治疗的现状与进展[J]. 医学与哲学, 2016, 37(6): 58-60. https://www.cnki.com.cn/Article/CJFDTOTAL-YXZL201603019.htm
    [3]
    邵晶, 刘敬杨, 徐睿玲, 等. 注射液胸腺法新(日达仙)辅助希罗达联合奥沙利铂(XELOX方案)治疗晚期胃癌的临床疗效观察[J]. 现代生物医学进展, 2016, 16(23): 4468-4471. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201623018.htm
    [4]
    高利民, 武彦芳. 胃癌及癌前疾病与血清胃泌素17的测定及其他影响因素研究[J]. 癌症进展, 2016, 14(8): 817-819. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ201608031.htm
    [5]
    张晓瑞. 替吉奥联合奥沙利铂治疗进展期胃癌的疗效观察[J]. 中国药物与临床, 2017, 17(1): 108-110. https://www.cnki.com.cn/Article/CJFDTOTAL-YWLC201701047.htm
    [6]
    王民开, 夏亚兰, 吴忠亮, 等. 两种新辅助化疗方案联合手术治疗进展期胃癌的疗效比较[J]. 重庆医学, 2018, 47(28): 3708-3709, 3711. doi: 10.3969/j.issn.1671-8348.2018.28.029
    [7]
    蒋强. 不同手术方式治疗弥漫型近端进展期胃癌患者的近期疗效及远期预后[J]. 医学临床研究, 2018, 35(4): 654-656. doi: 10.3969/j.issn.1671-7171.2018.04.010
    [8]
    肖康, 戈伟. 奥沙利铂联合卡培他滨的新辅助化疗治疗进展期胃癌的疗效及安全性[J]. 中国肿瘤临床与康复, 2016, 23(3): 261-263. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZK201603002.htm
    [9]
    李明辉, 刘红波, 冯运章. 康莱特腹腔热灌注联合XELOX方案化疗治疗进展期胃癌的疗效观察[J]. 现代肿瘤医学, 2017, 25(2): 266-269. doi: 10.3969/j.issn.1672-4992.2017.02.028
    [10]
    谢良宝, 高凌, 冯亚光. 卡培他滨联合奥沙利铂术前新辅助化疗对进展期胃癌手术患者临床疗效的影响[J]. 现代肿瘤医学, 2018, 26(13): 2076-2079. doi: 10.3969/j.issn.1672－4992.2018.13.027
    [11]
    吴凯, 冯许刚, 戴晓玲. 术前SOX方案新辅助化疗对局部进展期胃癌手术效果的影响[J]. 海南医学, 2016, 27(19): 3167-3169. doi: 10.3969/j.issn.1003-6350.2016.19.024
    [12]
    陈力, 张玉新, 左艳娇, 等. SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效比较[J]. 实用肿瘤学杂志, 2017, 31(1): 23-30. https://www.cnki.com.cn/Article/CJFDTOTAL-SYZL201701008.htm
    [13]
    吕文瑜, 陈绍水. SOX方案与XELOX方案治疗进展期胃癌的临床对比研究[J]. 癌症进展, 2017, 15(3): 304-307. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ201703024.htm
    [14]
    彭良群, 杨巍, 张占东, 等. 进展期胃癌患者新辅助化疗后病理完全缓解的影响因素[J]. 中华实用诊断与治疗杂志, 2017, 31(7): 697-699. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD201707021.htm
    [15]
    沈国杰, 朱侃恺, 邬一军, 等. 新辅助化疗联合胃癌根治术治疗进展期胃癌的临床疗效[J]. 中华消化外科杂志, 2017, 16(3): 240-244. doi: 10.3760/cma.j.issn.1673-9752.2017.03.005
    • Related Articles

  • Cited by

    Periodical cited type(9)

    1. 李易晨，柏承文. 免疫微生态肠内营养方案可改善重症急性胰腺炎患者肠道菌群和预后. 内科急危重症杂志. 2023(01): 26-29 .
    2. 江浩. 益生菌对重症急性胰腺炎患者免疫功能及血清TRF、PA、ALB、Hb水平的影响. 现代医学与健康研究电子杂志. 2021(03): 61-63 .
    3. 尚鸳鸳. 早期肠内营养支持对重症急性胰腺炎患者的临床疗效及安全性探讨. 临床医学工程. 2021(09): 1259-1260 .
    4. 薛静，李胜，谢文贤，秦健，缪婷，卢翠洁，王振，王浩. 益生菌联合早期肠内营养治疗重症急性胰腺炎临床疗效的Meta分析. 中国微生态学杂志. 2021(12): 1413-1419 .
    5. 廖健宏. 益生菌联合早期肠内营养对急性胰腺炎患者血浆白蛋白、C反应蛋白、淀粉酶及体质量等指标的影响研究. 现代消化及介入诊疗. 2020(03): 364-366 .
    6. 樊周沛，尹明明，李颖霞，温洪涛. 早期肠内营养对结肠癌患者术后康复进程和并发症的影响. 河南医学研究. 2020(18): 3300-3302 .
    7. 黄建，江钟立. 早期肠内营养重构肠道微生态促进缺血性脑卒中康复的研究. 现代消化及介入诊疗. 2019(04): 398-401 .
    8. 李明. 肠道微生态在急性胰腺炎发病和治疗中的应用研究进展. 世界最新医学信息文摘. 2019(58): 52-53 .
    9. 张紫盈，范正论. 早期肠内营养联合肠外营养对重症急性胰腺炎患者的临床研究. 临床医药文献电子杂志. 2019(94): 9 .

    Other cited types(3)

Catalog

    Get Citation
    PDF
    XML
    Article views PDF downloads Cited by(12)
    Turn off MathJax
    Article Contents
    Abstract
    References

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return